| |
|
|
|
|
| Slide Lecture Programs |
| 2004 Core Curriculum |
Impact of vascular biology on cardiovascular disease, risk prevention, and treatment
Section I: Atrial fibrillation, anticoagulation, and stroke prevention |
April 16, 2004
|
| E: |
Emerging new options
Profile of direct thrombin inhibition
- Elevation in ALT >3x the upper limit of normal occurred in 37 (6%) of the patients in the ximelagatran group and 6 (1%) in the placebo group.1
- As shown, ALT elevations in the ximelagatran group returned to baseline regardless of whether the drug was continued (n = 24) or discontinued (n = 13). The median time to normalization was 129 days.
1Schulman S, Wåhlander K, Lundström T, Clason SB, Eriksson H, for the THRIVE III investigators. Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran. N Engl J Med. 2003;349;1713-1721.
|
|
|
Resources